Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Pediatr Blood Cancer. 2021 Jun 9;68(9):e29174. doi: 10.1002/pbc.29174

TABLE 3.

Transplant Outcomes

Spanish Speaking
w/Limited English
Proficiency
(N=54)
English proficient
(N=29)
All
(N=83)
P-Value
Time from transplant to discharge1 0.0374
 Mean (SD) 46.66 (26.58) 33.42 (20.67) 41.77 (25.23)
 Median 36.00 31.00 34.00
 Range (16.00-138.00) (1.00-116.00) (1.00-138.00)
Post-transplantation CMV reactivation2 0.0685
 Yes 23 (59.0%) 2 (22.2%) 25 (52.1%)
 No 16 (41.0%) 7 (77.8%) 23 (47.9%)
Neutrophil Engraftment @ Day 423 91 (78, 96) 93 (71, 99) 92 (83, 96) 0.8086
Relapse @ 1 Year3 29 (16, 45) 19 (4, 41) 26 (15, 39) 0.1846
Acute GVHD @ 100 Days3 44 (29, 57) 50 (29, 68) 46 (34, 57) 0.3356
Chronic GVHD @ 1 Year3 20 (11, 32) 31 (15, 48) 24 (16, 34) 0.1786
1

Among patients discharged alive. A total of 5 English Proficient patients and 13 Spanish Speaking w/Limited English Proficiency died in the hospital.

2

Among patients who were seropositive prior to transplant

3

Cumulative incidence (with death as a competing risk) and 95% confidence intervals

4

Wilcoxon rank sum test

5

Fisher’s exact test

6

Gray’s test